Market Price

86.91 

-0.21 -0.2%

as of Mar 20 '19

52 Week Range:

53.14 94.01


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. It provides cardiovascular products comprising Epadel for arteriosclerosis obliterans and hyperlipidemia, Atelec and Atedio for hypertension, Rocornal for angina pectoris, and Treprost for pulmonary arterial hypertension; emergency products, such as Heparin Sodium for Inj. MOCHIDA for thrombosis, Miraclid for acute circulatory failure and acute pancreatitis, Thrombin for hemostatic, and Uronase for acute myocardial infarction; and other products, such as Tramcet for chronic pain and pain after tooth extraction, Fastic for diabetes, and Filgrastim BS Syringe for Inj. MOCHIDA for neutropenia. The company also offers OB/GYN products, such as Dinagest for endometriosis; Suprecur for endometriosis and central precocious puberty/uterine myoma; Doxil for the treatment of ovarian cancer; Estriel for menopausal disorders, osteoporosis, and vaginitis; Divigel for menopausal symptoms; and HCG Mochida for infertility, threatened miscarriage, and habitual abortion. In addition, it provides Lexapro for depression and depressive symptoms, Lialda for ulcerative colitis, and Goofice for chronic constipation; dermatology products, including Florid for mycosis; Arasena-A for herpes zoster, herpes simplex, and herpes simplex encephalitis; and Beselna Cream for condyloma acuminatum and actinic keratosis, as well as provides contract manufacturing services. Mochida Pharmaceutical Co., Ltd. has collaboration with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products. The company was founded in 1913 and is headquartered in Tokyo, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Equity (BVPS) 17.93
24.72
28.67
30.84
35.98
34.78
32.60
37.54
42.26
47.69
45.84
growth rate 37.9% 16.0% 7.6% 16.7% -3.3% -6.3% 15.2% 12.6% 12.9% -3.9%
Earnings BIT 16,602.00
11,690.00
12,156.00
11,374.00
11,663.00
growth rate -29.6% 4.0% -6.4% 2.5%
Avg.PE 16.20
16.14
15.82
growth rate -0.4% -2.0%
ROA 7.87
8.50
9.44
4.95
8.20
7.83
7.87
5.84
6.14
5.96
5.95
growth rate 8.0% 11.1% -47.6% 65.7% -4.5% 0.5% -25.8% 5.1% -2.9% -0.2%
ROE 11.23
11.81
12.82
6.76
11.32
10.72
10.86
7.84
8.01
7.87
7.79
growth rate 5.2% 8.6% -47.3% 67.5% -5.3% 1.3% -27.8% 2.2% -1.8% -1.0%
ROIC 10.82
11.52
12.67
6.61
11.23
10.62
10.76
7.79
7.96
7.87
7.79
growth rate 6.5% 10.0% -47.8% 69.9% -5.4% 1.3% -27.6% 2.2% -1.1% -1.0%
Cur. Ratio 3.39
3.18
3.51
3.34
3.33
3.42
3.23
4.09
3.96
3.70
3.93
growth rate -6.2% 10.4% -4.8% -0.3% 2.7% -5.6% 26.6% -3.2% -6.6% 6.2%
Quick Ratio 2.57
2.39
2.74
2.56
2.53
2.69
2.49
3.05
3.06
2.80
2.87
growth rate -7.0% 14.6% -6.6% -1.2% 6.3% -7.4% 22.5% 0.3% -8.5% 2.5%
Leverage 1.40
1.38
1.34
1.39
1.37
1.36
1.39
1.29
1.31
1.33
1.30
growth rate -1.4% -2.9% 3.7% -1.4% -0.7% 2.2% -7.2% 1.6% 1.5% -2.3%
Balance Sheet Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Acct.Receivable 27,784.00
27,981.00
26,002.00
26,199.00
30,793.00
31,769.00
growth rate 0.7% -7.1% 0.8% 17.5% 3.2%
Acct.Payable 10,284.00
11,575.00
10,244.00
11,255.00
17,058.00
16,497.00
growth rate 12.6% -11.5% 9.9% 51.6% -3.3%
Cur.Assets 86,692.00
93,842.00
91,904.00
102,043.00
112,016.00
116,302.00
growth rate 8.3% -2.1% 11.0% 9.8% 3.8%
Total Assets 120,828.00
130,669.00
127,557.00
137,713.00
148,372.00
155,054.00
growth rate 8.1% -2.4% 8.0% 7.7% 4.5%
Cash 29,109.00
33,135.00
31,016.00
28,916.00
46,308.00
45,683.00
growth rate 13.8% -6.4% -6.8% 60.2% -1.4%
Inventory 14,386.00
16,558.00
18,789.00
17,818.00
21,262.00
25,005.00
growth rate 15.1% 13.5% -5.2% 19.3% 17.6%
Cur.Liabilities 25,354.00
29,041.00
22,443.00
25,795.00
30,269.00
29,574.00
growth rate 14.5% -22.7% 14.9% 17.3% -2.3%
Liabilities 32,287.00
36,981.00
28,887.00
32,784.00
36,504.00
35,368.00
growth rate 14.5% -21.9% 13.5% 11.4% -3.1%
Equity 93,688.00
98,670.00
104,929.00
111,868.00
119,686.00
growth rate 5.3% 6.3% 6.6% 7.0%
Common Shares 24.00
23.00
23.00
22.00
21.00
21.00
20.00
20.00
20.00
20.00
20.00
growth rate -4.2% 0.0% -4.4% -4.6% 0.0% -4.8% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Capital Expenditures 2,043.00
2,435.00
1,930.00
1,827.00
1,106.00
1,095.00
growth rate 19.2% -20.7% -5.3% -39.5% -1.0%
Cash Dividends 2,796.00
3,359.00
2,826.00
2,726.00
3,422.00
growth rate 20.1% -15.9% -3.5% 25.5%
Cash From OA 11,909.00
12,478.00
5,122.00
15,211.00
5,583.00
3,283.00
growth rate 4.8% -59.0% 197.0% -63.3% -41.2%
FCF per Share 1.06
2.20
3.64
1.78
2.54
3.02
3.32
2.53
3.73
4.37
0.75
growth rate 107.6% 65.5% -51.1% 42.7% 18.9% 9.9% -23.8% 47.4% 17.2% -82.8%
Sale Purchase of Stock 1.00
1.00
growth rate 0.0%
FCF 3,997.00
6,734.00
10,316.00
4,603.00
7,198.00
9,866.00
10,043.00
3,192.00
13,384.00
4,477.00
2,188.00
growth rate 68.5% 53.2% -55.4% 56.4% 37.1% 1.8% -68.2% 319.3% -66.6% -51.1%
Income Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Sales 89,210.00
93,947.00
87,252.00
92,272.00
97,349.00
106,761.00
growth rate 5.3% -7.1% 5.8% 5.5% 9.7%
Op.Income 9,152.00
16,602.00
11,690.00
12,156.00
11,374.00
11,663.00
growth rate 81.4% -29.6% 4.0% -6.4% 2.5%
IBT 15,805.00
11,141.00
12,096.00
11,583.00
12,115.00
growth rate -29.5% 8.6% -4.2% 4.6%
Net Income 9,152.00
9,892.00
7,544.00
8,150.00
8,526.00
9,023.00
growth rate 8.1% -23.7% 8.0% 4.6% 5.8%
EPS 349.10
376.35
434.30
242.20
430.45
442.26
488.66
377.27
410.46
429.46
454.55
growth rate 7.8% 15.4% -44.2% 77.7% 2.7% 10.5% -22.8% 8.8% 4.6% 5.8%
Gross Profit 56,433.00
59,589.00
53,348.00
55,001.00
56,310.00
53,567.00
growth rate 5.6% -10.5% 3.1% 2.4% -4.9%
R&D 11,961.00
11,777.00
13,454.00
15,226.00
11,912.00
growth rate -1.5% 14.2% 13.2% -21.8%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 4,120.00
-547.00
6,169.00
1,454.00
3,664.00
growth rate -100.0% 100.0% -76.4% 152.0%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 36,069.00
31,769.00
37,319.00
33,371.00
37,082.00
growth rate -11.9% 17.5% -10.6% 11.1%
Acct.Payable 14,260.00
16,497.00
14,913.00
13,069.00
11,917.00
growth rate 15.7% -9.6% -12.4% -8.8%
Cur.Assets 115,099.00
116,302.00
116,892.00
114,868.00
114,852.00
growth rate 1.1% 0.5% -1.7% 0.0%
Total Assets 153,031.00
155,054.00
159,458.00
159,921.00
157,780.00
growth rate 1.3% 2.8% 0.3% -1.3%
Cash 41,728.00
45,683.00
41,686.00
47,212.00
46,106.00
growth rate 9.5% -8.8% 13.3% -2.3%
Inventory 23,526.00
25,005.00
25,446.00
24,327.00
21,626.00
growth rate 6.3% 1.8% -4.4% -11.1%
Cur.Liabilities 27,379.00
29,574.00
28,820.00
26,457.00
24,798.00
growth rate 8.0% -2.6% -8.2% -6.3%
Liabilities 33,346.00
35,368.00
34,538.00
32,082.00
30,357.00
growth rate 6.1% -2.4% -7.1% -5.4%
Equity 119,685.00
119,686.00
124,920.00
127,839.00
127,423.00
growth rate 0.0% 4.4% 2.3% -0.3%
Common Shares 7,229.00
7,229.00
7,229.00
7,229.00
7,229.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 29,142.00
23,031.00
29,800.00
27,436.00
30,402.00
growth rate -21.0% 29.4% -7.9% 10.8%
Op.Income 4,120.00
-547.00
6,169.00
1,454.00
3,664.00
growth rate -100.0% 100.0% -76.4% 152.0%
IBT 4,423.00
-549.00
7,839.00
1,466.00
3,818.00
growth rate -100.0% 100.0% -81.3% 160.4%
Net Income 3,348.00
-247.00
5,843.00
1,093.00
2,913.00
growth rate -100.0% 100.0% -81.3% 166.5%
Gross Profit 15,282.00
10,286.00
15,699.00
12,611.00
14,658.00
growth rate -32.7% 52.6% -19.7% 16.2%
R&D 11,912.00
11,912.00
growth rate 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (13.13)

YOY Growth Grade:

E (32.77)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 18.93 18.93
EPS / Growth 4.59

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 6.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 6.7% 6.7% 6.7%
Future PE 0.01 10.77 10.77
Future EPS 8.77 8.77 8.77
Value Price
MOS %
0.02
-100.0%
23.37
-73.1%
23.37
-73.1%
MOS Price 0.01 11.68 11.68
IRT 12.08 12.08 12.08

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.